Activity surrounding GlaxoSmithKline (GSK, Financial) has tilted bearish with a noticeable increase in options trading. A total of 3,615 put contracts have been traded, which is 1.6 times the usual volume for the pharmaceutical company. The most active options are the May 2025 $30 puts and the August 2025 $35 puts, collectively accounting for nearly 2,700 contracts. This significant put activity has resulted in a Put/Call Ratio of 10.42, highlighting a strong bearish sentiment in the market.
Additionally, the at-the-money implied volatility (ATM IV) has increased by over one point today, signaling expectations for potential price fluctuations in the near term. Investors are closely watching GSK as the company is set to release its earnings report on April 30th, which could further impact market movements and trader sentiment.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for GSK PLC (GSK, Financial) is $38.89 with a high estimate of $45.00 and a low estimate of $33.96. The average target implies an upside of 7.99% from the current price of $36.01. More detailed estimate data can be found on the GSK PLC (GSK) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, GSK PLC's (GSK, Financial) average brokerage recommendation is currently 2.8, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for GSK PLC (GSK, Financial) in one year is $41.87, suggesting a upside of 16.27% from the current price of $36.0099. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the GSK PLC (GSK) Summary page.
